279 related articles for article (PubMed ID: 27063195)
1. EZH2 as a mediator of treatment resistance in melanoma.
Tiffen JC; Gallagher SJ; Tseng HY; Filipp FV; Fazekas de St. Groth B; Hersey P
Pigment Cell Melanoma Res; 2016 Sep; 29(5):500-7. PubMed ID: 27063195
[TBL] [Abstract][Full Text] [Related]
2. NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.
De Donatis GM; Le Pape E; Pierron A; Cheli Y; Hofman V; Hofman P; Allegra M; Zahaf K; Bahadoran P; Rocchi S; Bertolotto C; Ballotti R; Passeron T
Oncogene; 2016 May; 35(21):2735-45. PubMed ID: 26364600
[TBL] [Abstract][Full Text] [Related]
3. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.
Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV
Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
5. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
7. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
Mahmoud F; Shields B; Makhoul I; Hutchins LF; Shalin SC; Tackett AJ
Cancer Biol Ther; 2016 Jun; 17(6):579-91. PubMed ID: 27105109
[TBL] [Abstract][Full Text] [Related]
8. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic mechanisms of tumor resistance to immunotherapy.
Arenas-Ramirez N; Sahin D; Boyman O
Cell Mol Life Sci; 2018 Nov; 75(22):4163-4176. PubMed ID: 30140960
[TBL] [Abstract][Full Text] [Related]
10. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
[TBL] [Abstract][Full Text] [Related]
11. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Qiu J; Sharma S; Rollins RA; Paul TA
Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
[TBL] [Abstract][Full Text] [Related]
12. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma.
Sanna L; Marchesi I; Melone MAB; Bagella L
J Cell Physiol; 2018 Sep; 233(9):6508-6517. PubMed ID: 29574790
[TBL] [Abstract][Full Text] [Related]
13. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
14. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
15. Polycomb repressive complex 2 is a critical mediator of allergic inflammation.
Keenan CR; Iannarella N; Garnham AL; Brown AC; Kim RY; Horvat JC; Hansbro PM; Nutt SL; Allan RS
JCI Insight; 2019 May; 4(10):. PubMed ID: 31092733
[TBL] [Abstract][Full Text] [Related]
16. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
17. Ezh2
Zimmerman SM; Nixon SJ; Chen PY; Raj L; Smith SR; Paolini RL; Lin PN; Souroullas GP
Oncogene; 2022 Nov; 41(46):4983-4993. PubMed ID: 36220978
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
19. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.
Fisher ML; Adhikary G; Grun D; Kaetzel DM; Eckert RL
Mol Carcinog; 2016 Dec; 55(12):2024-2036. PubMed ID: 26693692
[TBL] [Abstract][Full Text] [Related]
20. EZH2 inhibitors: a patent review (2014-2016).
Stazi G; Zwergel C; Mai A; Valente S
Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
